Evaxion to Develop Tailored Novel Cancer Vaccines Based upon a New Untapped Source of AI-Discovered Targets

January 24, 2024

https://www.globenewswire.com/news-release/2024/01/24/2815320/0/en/Evaxion-to-Develop-Tailored-Novel-Cancer-Vaccines-Based-upon-a-New-Untapped-Source-of-AI-Discovered-Targets.html

COPENHAGEN, Denmark, Jan. 24, 2024 (GLOBE NEWSWIRE) — Evaxion Biotech A/S (NASDAQ:EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces an expanded commitment to developing tailored cancer vaccines by targeting a novel category of AI-identified tumor antigens, named Endogenous Retroviruses (ERVs).

Read more at globenewswire.com

Related news for (EVAX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.